Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy by Berardi, R et al.
Oncotarget26916www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 18
Prognostic models to predict survival in patients with advanced 
non-small cell lung cancer treated with first-line chemo- or 
targeted therapy
Rossana Berardi1, Silvia Rinaldi1, Matteo Santoni1, Thomas Newsom-Davis2, 
Michela Tiberi3, Francesca Morgese1, Miriam Caramanti1, Agnese Savini1, Consuelo 
Ferrini1, Mariangela Torniai1, Ilaria Fiordoliva1, Marc Bower2 and Stefano Cascinu1,4
1 Clinica di Oncologia Medica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto 
I – GM Lancisi – G Salesi di Ancona, Ancona, Italy
2 Chelsea and Westminster Hospital, London, United Kingdom
3 Chirurgia Toracica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I – GM 
Lancisi – G Salesi di Ancona, Ancona, Italy
4 Oncologia Medica-Università degli Studi di Modena e Reggio Emilia, Modena, Italy
Correspondence to: Rossana Berardi, email: rossana.berardi@libero.it
Keywords: lung cancer; neutrophil to lymphocyte ratio; platinum-base chemotherapy; prognosis; targeted therapy
Received: November 11, 2015 Accepted: March 07, 2016 Published: March 23, 2016
ABSTRACT
Background: We aimed to assess the prognostic role of neutrophilia, 
lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models 
to define the prognosis of patients receiving first-line chemo- or targeted therapy for 
advanced non-small cell lung cancer (NSCLC). 
Materials and Methods: We retrospectively analysed 401 consecutive patients 
with advanced NSCLC treated with first line chemo- or targeted therapy. Patients were 
stratified into two groups with pre-treatment NLR ≥ 3.7 (Group A) vs. < 3.7 (Group 
B). The best NLR cut-off was identified by ROC curve analysis. 
Results: At baseline 264 patients had NLR≥3.7 (Group A), whilst 137 had lower 
NLR (Group B). Median OS was 10.8 months and 19.4 months in the two groups (p < 
0.001), while median PFS was 3.6 months and 5.6 months, respectively (p = 0.012). 
At multivariate analysis, ECOG-PS≥2, stage IV cancer, non-adenocarcinoma histology, 
EGFR wild-type status and NLR were predictors of worse OS. Stage IV cancer, wild 
type EGFR status and NLR≥3.7 were independent prognostic factors for worse PFS. 
Patients were stratified according to the presence of 0-1 prognostic factors (8%), 
2-3 factors (73%) and 4-5 factors (19%) and median OS in these groups was 33.7 
months, 14.6 months and 6.6 months, respectively (p < 0.001). Similarly, patients 
were stratified for PFS based on the presence of 0-1 prognostic factor (15%), 2 
factors (41%) and 3 factors (44%). The median PFS was 8.3 months, 4.6 months and 
3.3 months respectively (p < 0.001).
Conclusion: Pre-treatment NLR is an independent prognostic factor for patients 
with advanced NSCLC treated with first-line therapies.
INTRODUCTION
Lung cancer is the leading cause of cancer related 
death in both men and women [1]. Non-small cell lung 
cancer (NSCLC) accounts for approximately 85% of all 
lung cancers. NSCLC is often insidious, producing no 
symptoms until the disease is advanced. Over the past few 
years a variety of prognostic and predictive factors have 
been investigated in patients with NSCLC, and several 
prognostic models proposed to predict the outcome of 
patients with NSCLC after surgery [2−4] or chemotherapy 
and/or radiotherapy [5−6]. Despite this the prognosis for 
patient with advanced NSCLC remains dismal, and novel 
approaches are required in order to optimize patient 
outcomes and guide treatment decisions. 
Inflammation contributes to the pathogenesis 
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and progression of lung cancer. For example, chronic 
inflammatory lung diseases such as sarcoidosis and 
chronic obstructive pulmonary disease (COPD) are 
associated with a higher risk of lung cancer [7], whilst the 
chronic use of anti-inflammatory drugs seems to reduce 
the risk [8]. In vitro studies suggest that direct cell-cell 
interactions between neutrophils and NSCLC cells can 
induce the release of inflammatory mediators, which may 
promote tumor cell proliferation [9]. Indeed, NSCLC 
cells might secret immunoreactive IL-8 and stimulate 
polymorphonuclear neutrophils (PMNs) to release 
Arginase 1. Both molecules inhibit T-cell proliferation 
and favour tumor cell progression [10]. An elevated 
neutrophil count has been associated with poor prognosis 
in patients with NSCLC treated with chemotherapy, with 
a difference in overall survival (OS) of approximately 9 
months compared to those with normal neutrophil count 
(19.3 vs. 10.2 months) [11].
Markers of inflammation, such as the neutrophil-
to-lymphocyte ratio (NLR), and their clinical significance 
in NSCLC patients are still under evaluation. NLR is an 
easily measurable parameter of systemic inflammation. 
Increased pre-treatment NLR has been demonstrated 
to be associated with poor outcome for various types of 
cancers including gastric cancer [12], advanced pancreatic 
cancer [13], hepatocellular carcinoma [14], colorectal 
Table 1: Patient characteristics.
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liver metastases [15], bladder cancer [16], malignant 
mesothelioma [17], ovarian cancer [18] and renal cell 
carcinoma [19−22]. 
The aim of this study was to assess the prognostic 
role of pre-treatment neutrophilia, lymphocytopenia and 
NLR and to design a model to define the prognosis of 




Five hundreds and twenty-one patients were treated 
with first-line therapies. Of these, 401 patients (275 males 
and 126 female) were included in the NLR analysis, while 
120 patients were excluded for the lack of data on pre-
treatment NLR. 
The median age was 68y (range 25−86). The 
majority were current or former smokers (323 patients, 
81%). Histology was adenocarcinoma in 258 patients 
(64%), squamous carcinoma in 94 patients (23%) and 
other histology in 49 patients (13%). One hundred 
and twenty-one (30%) patients have stage III and 280 
patients (70%) has stage IV disease. First-line therapy 
involved chemotherapy in 373 patients (93%) and EGFR-
TKIs in 28 patients (7%). The complete list of patients’ 
characteristics is summarized in Table 1. 
The median neutrophil count was 7020/mm³, 
median lymphocyte count was 1400/mm³ and median 
NLR was 5.1. Absolute neutrophilia (≥7500/mm3) was 
present in 179 patients (45%), while lymphocytopenia ( < 
1500/mm3) was reported in 87 patients (22%).
The best NLR cut-off was ≥ 3.7 vs. < 3.7, as 
identified by ROC curve analysis (Figure 1). Patients 
were further divided into two groups according to NLR. 
Two hundred and sixty-four patients (66%) had NLR ≥ 3.7 
at baseline (Group A), while 137 (34%) had lower NLR 
(Group B). 
Overall survival (OS)
The median OS from first-line therapy was 14.4 
months (95% CI 12.4 to 16.9) in the total population. Two 
hundred and forty eight patients died during follow-up. 
The median OS was 19.6 months (95% CI 16.5 to 
28.6) in the 78 non-smokers and 13.1 months (95% CI 
10.8 to 16.0) in the 323 smokers (p = 0.08). Stratified by 
gender, the median OS was 11.7 months (95% CI 9.5 to 
15.5) in males and 18.4 months (95% CI 14.4 to 27.9) 
in females (p = 0.005). No significant difference was 
Table 2: Univariate and multivariable analysis of predictors of OS in patients treated with first-line therapy for locally 
advanced or metastatic NSCLC.
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found between patients aged < 70y vs. ≥70y (14.7 vs. 14.4 
months, p = 0.335). Patients with ECOG-PS ≥ 2 had a 
significantly shorter OS compared to those with ECOG-PS 
< 2 (4.6 vs. 15.5 months, p < 0.001).
With respect to histology, the median OS was 11.9 
months (95% CI 9.5 to 15.5) in patients with squamous 
carcinoma, 16.2 months (95% CI 13.4 to 22.0) for 
adenocarcinoma and 12.7 months (95% CI 9.6 to 16.8) for 
other histologies (p = 0.053).
The median OS was 9.7 months (95% CI 7.4 to 
14.4) and 16.9 months (95% CI 14.4 to 20.6) for patients 
with and without absolute neutrophilia, respectively (p < 
0.001) (Figure 2A). No significant difference was found 
between patients with and without lymphocytopenia (13.7 
vs. 14.5 months, p = 0.319).
Stratified by NLR ≥ 3.7 vs. < 3.7, the median OS 
was 10.8 months (95% CI 9.3 to 14.7) in Group A and 
19.4 months (95% CI 15.0 to 29.1) in Group B (p < 0.001) 
(Figure 3A). 
Univariate analysis showed that gender (male), 
ECOG-PS ≥ 2, current or former smokers, tumor stage IV, 
non-adenocarcinoma histology, wild-type EGFR status, 
neutrophilia and NLR ≥ 3.7 were significantly associated 
with worse OS (Table 2). At multivariate analysis, ECOG-
PS, tumor stage, histology, EGFR status and NLR were 
predictors of OS (Table 2). 
Progression-free survival (PFS) and response to 
first-line therapy
The median PFS was 4.1 months (95% CI 3.6 to 
4.8) in the overall study population, 3.7 months (95% CI 
3.3 to 4.4) in males and 5.4 months (95% CI 4.4 to 6.9) in 
females (p = 0.04).
The median PFS was 5.8 months (95% CI 3.9 to 8.7) 
in the 78 non-smokers and 4.1 months (95% CI 3.6 to 4.8) 
in the 323 smokers (p = 0.08). No significant difference 
was found with respect to age < 70y vs. ≥70y (3.9 vs. 4.2 
months, p = 0.945), ECOG-PS ≥ 2 vs. < 2 (3.7 vs. 4.2 
months, p = 0.10), or histology (squamous carcinoma vs. 
adenocarcinoma vs. other histologies: 3.9 vs. 4.4 vs. 4 
months).
Median PFS was 3.6 months (95% CI 3.2 to 4.4) 
and 4.8 months (95% CI 3.9 to 5.6) in patients with and 
without absolute neutrophilia, respectively (p = 0.031) 
(Figure 2B). Similarly to OS, no difference was found 
between patients with and without lymphocytopenia (3.7 
vs. 4.2 months, p = 0.42).
Stratified by NLR, the median PFS was 3.6 months 
(95% CI 3.2 to 4.2) in Group A and 5.6 months (95% CI 
4.6 to 7.4) in Group B (p = 0.012) (Figure 3B). 
Furthermore, univariate analysis showed that gender 
(male), ECOG-PS ≥ 2, current or former smokers, tumor Figure 1: Cut-off identification by ROC curve.
Figure 2: OS (2A) and PFS (2B) stratified by the presence of neutrophilia in patients treated with first-line therapy for 
locally advanced or metastatic NSCLC. 
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stage IV, wild-type EGFR status, neutrophilia and NLR ≥ 
3.7 were significantly associated with worst PFS (Table 3). 
Multivariate Cox regression analysis revealed that tumor 
stage IV, wild-type EGFR status and NLR ≥ 3.7 were 
independent prognostic factors for worse PFS (Table 3).
As for response to first-line therapy, we compared 
by chi-squared test the rate of disease progressions in 
patients with NLR ≥ 3.7 vs. < 3.7. In the subgroup with 
higher NLR, the progression rate was 81% vs 71% in 
patients with NLR < 3.7, showing a significant difference 
between these two populations (p = 0.03).
Prognostic models for OS and PFS
Based on the multivariate analysis, ECOG-PS, 
tumor stage, histology, EGFR status and NLR were 
significantly associated with OS. A prognostic model was 
therefore created, stratifying patients according to the 
presence of 0-1 of these prognostic factor (33 patients, 
8%), 2-3 factors (293 patients, 73%) and 4-5 factors (75 
patients, 19%). In the 3 groups, the median OS was 33.7 
months (95% CI 29.5 to N.A.), 14.6 months (95% CI 12.7 
to 17.4) and 6.6 months (95% CI 4.9 to 9.7), respectively 
(p < 0.001; Figure 4A).
As a sensitivity analysis, we evaluated our 
prognostic model also in patients with EGFR wild-type 
tumors. In this subgroup, OS was 32.8 (95% CI 28.3 to 
N.A.), 14.4 (95% CI 12.2 to 17.4) and 9.7 (95% CI 4.9 
to 11.8) months in patients with 0-1, 2-3 or 4-5 factors, 
respectively (p = 0.041, Figure S1).
A similar prognostic model based on the multivariate 
analysis for PFS was created, with patients stratified on 
the presence of 0-1 factor (60 patients, 15%), 2 factors 
(166 patients, 41%) and 3 factors (175 patients, 44%). The 
median PFS was 8.3 months (95% CI 6.3 to 11.2), 4.6 
months (95% CI 3.9 to 5.8) and 3.3 months (95% CI 3.0 
to 3.9), respectively (p < 0.001; Figure 4B).
DISCUSSION
A better understanding of the complexity of 
tumor-immune interactions in patients with NSCLC 
has facilitated an increased interest and development of 
immune therapeutic strategies. However the effects of 
chemotherapy and targeted agents on the immune system 
and its role in tumour response to therapies remains less 
clear.
Previous groups have examined pre-treatment NLR 
in NSCLC. In early-stage disease, NLR was positively 
associated with the prognosis for patients treated with 
stereotactic radiation [23] and surgery [24−26]. Zhang et 
al. showed that preoperative lymphocytopenia correlated 
with lymphatic invasion and a shorter disease-free survival 
(DFS, 318 vs. 669 days) in 142 patients with NSCLC who 
underwent lobectomy and lymph node dissection and 
adjuvant chemotherapy. Neutrophil count however was 
Table 3: Univariate and multivariable analysis of predictors of PFS in patients treated with first-line 
therapy for locally advanced or metastatic NSCLC.
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not associated with DFS [27]. Elevated pre-treatment 
NLR was significantly associated with worse OS in 81 
advanced EGFR-mutated NSCLC patients treated with 
first-line EGFR TKIs [28], as well as in 199 never smokers 
with advanced NSCLC receiving gefitinib or standard 
chemotherapy [29]. In addition, Yao et al. found that high 
NLR was associated with shorter OS and PFS in patients 
with advanced NSCLC treated with first-line platinum-
based chemotherapy [30]. More recently, three different 
meta-analyses have confirmed the prognostic role of NLR 
in patients with lung cancer [31−33]. 
To the best of our knowledge, this is the largest study 
investigating for the role of neutrophilia, lymphocytopenia 
and NLR in patients with NSCLC treated with first-line 
therapies. In our study, ECOG-PS ≥ 2, IV tumor stage, 
non-adenocarcinoma histology, EGFR wild-type status 
and NLR were predictors of worse OS, whilst tumor 
stage IV, wild-type EGFR status and NLR ≥ 3.7 were 
independent prognostic factors for worse PFS. Based on 
these data, we designed two prognostic models for OS 
and PFS. Median OS differed according to the presence of 
0-1, 2-3 or 4-5 prognostic factors, thus identifying patients 
with good, intermediate and poor prognosis (33.7 months 
vs. 14.6 months vs. 6.6 months, p < 0.001). Similarly, 
when patients were stratified according to the presence of 
0-1, 2 or 3 prognostic factors for PFS, different duration of 
response to first-line therapies became evident (8.3 months 
vs. 4.6 months vs. 3.3 months, p < 0.001).
There are some limitations to this study. First, this 
is a retrospective study, which is susceptible to bias in 
data selection and analysis. Other inflammatory markers 
such as C-reactive protein (CRP) or procalcitonin, are not 
routinely measured in our institutions and so were not 
included. Furthermore, NLR differs among individuals and 
can present fluctuations due to concurrent infections and 
other medications, factors that cannot be fully accounted 
for in this study. Moreover, some patients (13/41) with 
EGFR mutated tumors were not treated with EGFR-TKIs 
Figure 3: OS (3A) and PFS (3B) stratified by neutrophil to lymphocyte ratio (NLR) in patients treated with first-line 
therapy for locally advanced or metastatic NSCLC. 
Figure 4: Prognostic models for OS (4A) and PFS (4B) in patients treated with first-line therapy for locally advanced 
or metastatic NSCLC.
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as first-line therapy due to unavailable data on EGFR 
mutational status at time of the beginning of treatment. 
Despite these limitations, our study suggests that 
pre-treatment NLR is associated with PFS and OS in 
patients treated with first-line therapies for advanced 
NSCLC. Prospective studies are needed to evaluate 
and validate the prognostic models described here and 
adequately assess the potential role of NLR in guiding 
treatment decisions, patient selection, and clinical trials 
design. 
MATERIALS AND METHODS
Study population and data collection
The study population was adults with a histological 
or cytological diagnosis of locally advanced or metastatic 
NSCLC treated with first-line chemotherapy or targeted 
therapy according to EGFR mutational status at two 
institutions (Università Politecnica Marche, Italy and 
Chelsea & Westminster Hospital, UK) between 1st May 
2009 and 31th October 2014. Tumor stages were assessed 
according to the tumor-node-metastasis (TNM) criteria 
and included patients with stage IIIB and IV, as well as 
patients in stage IIIA not suitable for surgery, as defined in 
AJCC version 7 [34]. 
Patients were ineligible if they had received surgery 
or radiotherapy within one month from the start of first-
line therapy and if they presented factors that could 
influence NLR (see below). Data was retrospectively 
collected from patients’ medical records. 
Treatment with first-line chemotherapy or TKIs 
was continued until evidence of disease progression on 
scans, unacceptable adverse events, or death. Follow-
up generally consisted of regular physical examination 
and laboratory assessment (hematologic and serum 
biochemical measurements), and imaging studies by 
computed tomography (CT) or magnetic resonance 
imaging (MRI) scans was carried out according to local 
procedures every 8-12 weeks.
The OS was defined as the time from the beginning 
of first-line treatment until death from any cause. 
Progression free survival (PFS) was defined as the time 
from beginning of treatment to disease progression or 
death from any cause. Patients without tumour progression 
or death at the time of the data cut-off for the analysis or at 
the time of receiving an additional anticancer therapy were 
censored at their last date of adequate tumour evaluation. 
Peripheral blood samples were obtained 1 to 
7 days before the start of first-line therapy. Patients 
without available data on pre-treatment NLR and those 
with baseline comorbidities that might influence NLR, 
such as chronic lymphocytic leukaemia (CLL), chronic 
inflammatory diseases, and recent signs of infection or 
therapy with steroids or granulocyte colony stimulating 
factor (G-CSF), were excluded.
Statistical analysis
PFS and OS were estimated using Kaplan-Meier 
method with Rothman’s 95% confidence intervals (CI) 
and compared across the groups using the log-rank test. 
Patients with a stable disease (SD), partial remission, and 
a complete remission were considered as responders.
Pre-treatment NLR was calculated by dividing the 
absolute neutrophil count by the absolute lymphocyte 
count and potential factors associated with outcome were 
evaluated, including patients’ age (≥ 70y vs. < 70y), 
gender, tumor stage, histology, EGFR mutational status, 
Eastern Cooperative Oncology Group-Performance 
Status (ECOG-PS), smoking history, neutrophil count, 
lymphocyte count, and NLR. We determined by ROC 
analysis the value that best discriminated between good 
and poor survival. 
Cox proportional hazards models were applied to 
explore patients’ characteristics predictors of survival in 
univariate- and multivariable analysis. Variables not fitting 
at univariate analysis were excluded from the multivariate 
model. No-multicollinearity of the grouped co-variates 
was checked. Significance level in the univariate model 
for inclusion in the multivariate final model was more 
liberally set at a 0.2 level, according to Hosmer et al. 
[35,36]. The likelihood ratio test was conducted to evaluate 
the improvement in prediction performance gained by 
backward elimination of variables from the prognostic 
model [37]. All other significance levels were set at a 0.05 
value and all P values were two-sided. Statistical analyses 
were performed using MedCalc version 11.4.4.0 (MedCalc 
Software, Broekstraat 52, 9030 Mariakerke, Belgium).
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